We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy (ReVIVE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05359653
Recruitment Status : Not yet recruiting
First Posted : May 4, 2022
Last Update Posted : November 2, 2022
Sponsor:
Collaborator:
United States Department of Defense
Information provided by (Responsible Party):
University of California, San Francisco

Brief Summary:

The clinical trial is intended to assess for clinical evidence of Clemastine Fumarate as a myelin repair therapy in patients with chronic inflammatory injury-causing demyelination as measured by multi-parametric MRI assessments.

No reparative therapies exist for the treatment of multiple sclerosis. Clemastine fumarate was identified along with a series of other antimuscarinic medications as a potential remyelinating agent using the micropillar screen (BIMA) developed at the University of California, San Francisco (UCSF). Following in vivo validation, an FDA IND exemption was granted to investigate clemastine for the treatment of multiple sclerosis in the context of chronic optic neuropathy. That pilot study was recently completed and is the first randomized control trial documenting efficacy for a putative remyelinating agent for the treatment of MS. The preselected primary efficacy endpoint (visual evoked potential) was met and a strong trend to benefit was seen for the principal secondary endpoint assessing function (low contrast visual acuity). That trial number was 13-11577.

This study seeks to follow up on that study and examine clemastine fumarate's protective and reparative effects in the context of chronic demyelinating brain lesions as imaged by multi-parametric MRI assessments. The investigators will be assessing the effects of clemastine fumarate as a remyelinating therapy and assessing its effect on MRI metrics of chronic lesions found in patients with a confirmed diagnosis of relapsing-remitting multiple sclerosis.

In addition to using conventional multi-parametric MRI assessments, this study will also evaluate a new MRI technique called Ultrashort Echo Time (UTE) MRI to assess the effects of clemastine fumarate as a remyelinating therapy of chronic lesions found in patients with a confirmed diagnosis of relapsing-remitting multiple sclerosis and compare it to the other assessments.


Condition or disease Intervention/treatment Phase
Multiple Sclerosis (MS) Multiple Sclerosis, Relapsing-Remitting Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Chronic Progressive Multiple Sclerosis Relapse Multiple Sclerosis Brain Lesion Multiple Sclerosis Benign Drug: Clemastine Fumarate Drug: Placebo Phase 1 Phase 2

Detailed Description:

Treatments capable of remyelination are a major unmet need for multiple sclerosis and other diseases that involve myelin damage, loss, or dysfunction in the central nervous system (CNS). Chronic demyelination of axons is believed to be injurious to neurons and serves as a major contributor to irreversible cell loss that underlies permanent disability. Available MS treatments are primarily immunosuppressing, without directly addressing or fully preventing axonal degeneration and disability. Clemastine fumarate was identified along with a series of other antimuscarinic medications as a potential remyelinating agent using the micropillar screen (BIMA) developed at UCSF. The screen demonstrated that clemastine promoted the differentiation of the endogenous oligodendrocyte precursor cells (OPCs) into mature myelinating oligodendrocytes. Following in vivo validation, an FDA investigational new drug (IND) exemption was granted to investigate clemastine for the treatment of multiple sclerosis in the context of chronic optic neuropathy. That pilot study was recently completed and is the first randomized control trial documenting efficacy for a putative remyelinating agent for the treatment of MS. The preselected primary efficacy endpoint (visual evoked potential) was met and a strong trend to benefit was seen for the principal secondary endpoint assessing function (low contrast visual acuity). That trial number was 13-11577.

This clinical trial is intended to assess magnetic resonance imaging evidence of remyelination using Clemastine Fumarate in patients with chronic demyelinated lesions. Specifically speaking, the primary objective will assess various multi-parametric MRI sequences on the corpus callosum region, a region that animal models studies identified as a promising candidate for assessing remyelination. The aim was to help define the potential for MRI in measuring remyelination in MS, determine the optimal sequences and location for measuring myelin recovery, and help guide trial design for future remyelinating trials. Finally, the study is designed to assess tolerability and clinical efficacy of Clemastine using outcomes intended to assess for (a) adverse events and (b) recovery of myelin.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 74 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description:

This is a 6-month randomized double-blinded, placebo-controlled, delayed treatment study examining clemastine fumarate as a remyelinating agent in participants with multiple sclerosis. This trial will include n = 74 patients with a confirmed diagnosis of relapsing-remitting multiple sclerosis.

Patients who fulfill the enrollment criteria will be randomly assigned (1:1) via block randomization using a random number generator to receive either clemastine for 90 days followed by placebo for 90 days (Clemastine 8 mg, then Placebo) or placebo for 90 days followed by clemastine for 90 days (Placebo, then Clemastine 8 mg).

If they are on one, patients will be permitted to remain on their standard disease-modifying treatment during the course of the study. These therapies have no identified effect on remyelination.

Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Delayed Treatment, Placebo-Controlled Trial to Assess the Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy
Estimated Study Start Date : December 1, 2022
Estimated Primary Completion Date : December 1, 2024
Estimated Study Completion Date : December 31, 2024


Arm Intervention/treatment
Experimental: Clemastine 8 mg, then Placebo
Group 1 will receive the treatment (clemastine 8mg/day) for the first 90 days and then switch to the placebo (a sugar pill) for the remaining 90 days
Drug: Clemastine Fumarate
8 mg Clemastine tablet. Clemastine fumarate was approved by the Food and Drug Administration (FDA) for the treatment of allergic rhinitis (seasonal allergies) in 1977 and was approved for over-the-counter marketing in 1992. Clemastine is not FDA approved as a remyelinating therapy
Other Names:
  • Clemastine
  • Dayhist
  • Dayhist Allergy

Drug: Placebo
Matched sugar tablet
Other Name: Sugar pill

Experimental: Placebo, then Clemastine 8 mg
Group 2 will receive the placebo (a sugar pill) for the first 90 days and then switch to the treatment (clemastine 8mg/day) for the remaining 90 days
Drug: Clemastine Fumarate
8 mg Clemastine tablet. Clemastine fumarate was approved by the Food and Drug Administration (FDA) for the treatment of allergic rhinitis (seasonal allergies) in 1977 and was approved for over-the-counter marketing in 1992. Clemastine is not FDA approved as a remyelinating therapy
Other Names:
  • Clemastine
  • Dayhist
  • Dayhist Allergy

Drug: Placebo
Matched sugar tablet
Other Name: Sugar pill




Primary Outcome Measures :
  1. Corpus Callosum Myelin Water Fraction [ Time Frame: This will be assessed at the baseline visit. ]
    The efficacy of clemastine relative to placebo at increasing the myelin water fraction (MWF) (measured in %) from magnetic resonance imaging of the corpus callosum.

  2. Change from Baseline in Corpus Callosum Myelin Water Fraction at 3 Months [ Time Frame: This will be assessed at the baseline and 3-month visits. ]
    The efficacy of clemastine relative to placebo at increasing the myelin water fraction (MWF) (measured in %) from magnetic resonance imaging of the corpus callosum. Change = (3-month % - Baseline %)

  3. Change from Baseline in Corpus Callosum Myelin Water Fraction at 6 Months [ Time Frame: This will be assessed at the baseline and 6-month visits. ]
    The efficacy of clemastine relative to placebo at increasing the myelin water fraction (MWF) (measured in %) from magnetic resonance imaging of the corpus callosum. Change = (6-month % - Baseline %)

  4. Corpus Callosum T1 Relaxation Time [ Time Frame: This will be assessed at the baseline visit. ]
    The efficacy of clemastine relative to placebo at shortening the T1 relaxation time (measured in seconds) within the corpus callosum using T1 mapping protocols in an MRI.

  5. Change from Baseline in Corpus Callosum T1 Relaxation Time at 3 Months [ Time Frame: This will be assessed at the baseline and 3-month visits. ]
    The efficacy of clemastine relative to placebo at shortening the T1 relaxation time (measured in seconds) within the corpus callosum using T1 mapping protocols in an MRI. Change = (3-month time - Baseline time)

  6. Change from Baseline in Corpus Callosum T1 Relaxation Time at 6 Months [ Time Frame: This will be assessed at the baseline and 6-month visits. ]
    The efficacy of clemastine relative to placebo at shortening the T1 relaxation time (measured in seconds) within the corpus callosum using T1 mapping protocols in an MRI. Change = (6-month time - Baseline time)

  7. Corpus Callosum UTE Fraction [ Time Frame: This will be assessed at the baseline visit. ]
    The efficacy of clemastine relative to placebo at increasing the ultrashort echo time (UTE) fraction (measured in %) derived from magnetic resonance imaging of the corpus callosum.

  8. Change from Baseline in Corpus Callosum UTE Fraction at 3 Months [ Time Frame: This will be assessed at the baseline and 3-month visits. ]
    The efficacy of clemastine relative to placebo at increasing the ultrashort echo time (UTE) fraction (measured in %) derived from magnetic resonance imaging of the corpus callosum. Change = (3-month % - Baseline %)

  9. Change from Baseline in Corpus Callosum UTE Fraction at 6 Months [ Time Frame: This will be assessed at the baseline and 6-month visits. ]
    The efficacy of clemastine relative to placebo at increasing the ultrashort echo time (UTE) fraction (measured in %) derived from magnetic resonance imaging of the corpus callosum. Change = (6-month % - Baseline %)


Secondary Outcome Measures :
  1. Optic Radiation Myelin Water Fraction [ Time Frame: This will be assessed at the baseline visit. ]
    The efficacy of Clemastine relative to placebo at increasing the MWF (measured in %) of the optic radiation.

  2. Change from Baseline in Optic Radiation Myelin Water Fraction at 3 Months [ Time Frame: This will be assessed at the baseline and 3-month visits. ]
    The efficacy of clemastine relative to placebo at increasing the MWF (measured in %) of the optic radiation. Change = (3-month % - Baseline %)

  3. Change from Baseline in Optic Radiation Myelin Water Fraction at 6 Months [ Time Frame: This will be assessed at the baseline and 6-month visits. ]
    The efficacy of clemastine relative to placebo at increasing the MWF (measured in %) of the optic radiation. Change = (6-month % - Baseline %)

  4. Corticospinal Tract Myelin Water Fraction [ Time Frame: This will be assessed at the baseline visit. ]
    The efficacy of clemastine relative to placebo at increasing the MWF (measured in %) of the corticospinal tract.

  5. Change from Baseline in Corticospinal Tract Myelin Water Fraction at 3 Months [ Time Frame: This will be assessed at the baseline and 3-month visits. ]
    The efficacy of clemastine relative to placebo at increasing the MWF (measured in %) of the corticospinal tract. Change = (3-month % - Baseline %)

  6. Change from Baseline in Corticospinal Tract Myelin Water Fraction at 6 Months [ Time Frame: This will be assessed at the baseline and 6-month visits. ]
    The efficacy of clemastine relative to placebo at increasing the MWF (measured in %) of the corticospinal tract. Change = (6-month % - Baseline %)

  7. Optic Radiation T1 Relaxation time [ Time Frame: This will be assessed at the baseline visit. ]
    To evaluate the efficacy of Clemastine relative to placebo at increasing the T1 relaxation time (measured in seconds) of the optic radiation.

  8. Change from Baseline in Optic Radiation T1 Relaxation Time at 3 Months [ Time Frame: This will be assessed at the baseline and 3-month visits. ]
    To evaluate the efficacy of Clemastine relative to placebo at increasing the T1 relaxation time (measured in seconds) of the optic radiation. Change = (3-month time - Baseline time)

  9. Change from Baseline in Optic Radiation T1 Relaxation Time at 6 Months [ Time Frame: This will be assessed at the baseline and 6-month visits. ]
    To evaluate the efficacy of Clemastine relative to placebo at increasing the T1 relaxation time (measured in seconds) of the optic radiation. Change = (6-month % - Baseline %)

  10. Corticospinal Tract T1 Relaxation Time [ Time Frame: This will be assessed at the baseline visit. ]
    To evaluate the efficacy of Clemastine relative to placebo at increasing the T1 relaxation time (measured in seconds) of the corticospinal tract.

  11. Change from Baseline in Corticospinal T1 Relaxation Time at 3 Months [ Time Frame: This will be assessed at the baseline and 3-month visits. ]
    To evaluate the efficacy of Clemastine relative to placebo at increasing the T1 relaxation time (measured in seconds) of the corticospinal tract. Change = (3-month time - Baseline time)

  12. Change from Baseline in Corticospinal Tract T1 Relaxation Time at 6 Months [ Time Frame: This will be assessed at the baseline and 6-month visits. ]
    To evaluate the efficacy of Clemastine relative to placebo at increasing the T1 relaxation time (measured in seconds) of the corticospinal tract. Change = (6-month % - Baseline %)

  13. Optic radiation UTE Fraction [ Time Frame: This will be assessed at the baseline visit. ]
    The efficacy of clemastine relative to placebo at increasing the UTE fraction (measured in %) of the optic radiation.

  14. Change from Baseline in Optic radiation UTE Fraction at 3 Months [ Time Frame: This will be assessed at the baseline and 3-month visits. ]
    The efficacy of clemastine relative to placebo at increasing the UTE fraction (measured in %) of the optic radiation. Change = (3-month % - Baseline %)

  15. Change from Baseline in Optic radiation UTE Fraction at 6 Months [ Time Frame: This will be assessed at the baseline and 6-month visits. ]
    The efficacy of clemastine relative to placebo at increasing the UTE fraction (measured in %) of the optic radiation. Change = (6-month % - Baseline %)

  16. Corticospinal Tract UTE Fraction [ Time Frame: This will be assessed at the baseline visit. ]
    The efficacy of clemastine relative to placebo at increasing the UTE fraction (measured in %) of the corticospinal tract.

  17. Change from Baseline in Corticospinal Tract UTE Fraction at 3 Months [ Time Frame: This will be assessed at the baseline and 3-month visits. ]
    The efficacy of clemastine relative to placebo at increasing the UTE fraction (measured in %) of the corticospinal tract. Change = (3-month % - Baseline %)

  18. Change from Baseline in Corticospinal Tract UTE Fraction at 6 Months [ Time Frame: This will be assessed at the baseline and 6-month visits. ]
    The efficacy of clemastine relative to placebo at increasing the UTE fraction (measured in %) of the corticospinal tract. Change = (6-month % - Baseline %)

  19. Lesion of interest (LOI) MWF [ Time Frame: This will be assessed at the baseline visit. ]
    The efficacy of clemastine relative to placebo at increasing MWF (measured in %) of the lesion(s) of interest, stratified based on enhancement status on prior MRIs.

  20. Change from Baseline in LOI MWF at 3 Months [ Time Frame: This will be assessed at the baseline and 3-month visits. ]
    The efficacy of clemastine relative to placebo at increasing MWF (measured in %) of the lesion(s) of interest, stratified based on enhancement status on prior MRIs. Change = (3-month % - Baseline %)

  21. Change from Baseline in LOI MWF at 6 Months [ Time Frame: This will be assessed at the baseline and 6-month visits. ]
    The efficacy of clemastine relative to placebo at increasing MWF (measured in %) of the lesion(s) of interest, stratified based on enhancement status on prior MRIs. Change = (6-month % - Baseline %)

  22. LOI T1 Relaxation Time [ Time Frame: This will be assessed at the baseline visit. ]
    The efficacy of clemastine relative to placebo at increasing T1 relaxation time (measured in seconds) of the lesion(s) of interest, stratified based on enhancement status on prior MRIs.

  23. Change from Baseline in LOI T1 Relaxation Time at 3 Months [ Time Frame: This will be assessed at the baseline and 3-month visits. ]
    The efficacy of clemastine relative to placebo at increasing T1 relaxation time (measured in seconds) of the lesion(s) of interest, stratified based on enhancement status on prior MRIs. Change = (3-month time - Baseline time)

  24. Change from Baseline in LOI T1 Relaxation Time at 6 Months [ Time Frame: This will be assessed at the baseline and 6-month visits. ]
    The efficacy of clemastine relative to placebo at increasing T1 relaxation time (measured in seconds) of the lesion(s) of interest, stratified based on enhancement status on prior MRIs. Change = (6-month time - Baseline time)

  25. LOI UTE Fraction [ Time Frame: This will be assessed at the baseline visit. ]
    The efficacy of clemastine relative to placebo at increasing UTE fraction (measured in %) of the lesion(s) of interest, stratified based on enhancement status on prior MRIs.

  26. Change from Baseline in LOI UTE Fraction at 3 Months [ Time Frame: This will be assessed at the baseline and 3-month visits. ]
    The efficacy of clemastine relative to placebo at increasing UTE fraction (measured in %) of the lesion(s) of interest, stratified based on enhancement status on prior MRIs. Change = (3-month % - Baseline %)

  27. Change from Baseline in LOI UTE Fraction at 6 Months [ Time Frame: This will be assessed at the baseline and 6-month visits. ]
    The efficacy of clemastine relative to placebo at increasing UTE fraction (measured in %) of the lesion(s) of interest, stratified based on enhancement status on prior MRIs. Change = (6-month % - Baseline %)

  28. Whole Brain MWF [ Time Frame: This will be assessed at the baseline visit. ]
    The efficacy of clemastine relative to placebo at increasing MWF (measured in %) across the whole-brain divided into regions of normal-appearing white matter (NAWM), cortical gray matter, and deep gray matter.

  29. Change from Baseline in Whole Brain MWF at 3 Months [ Time Frame: This will be assessed at the baseline and 3-month visits. ]
    The efficacy of clemastine relative to placebo at increasing MWF (measured in %) across the whole-brain divided into regions of normal-appearing white matter (NAWM), cortical gray matter, and deep gray matter. Change = (3-month % - Baseline %)

  30. Change from Baseline in Whole Brain MWF at 6 Months [ Time Frame: This will be assessed at the baseline and 6-month visits. ]
    The efficacy of clemastine relative to placebo at increasing MWF (measured in %) values across the whole-brain divided into regions of normal-appearing white matter (NAWM), cortical gray matter, and deep gray matter. Change = (6-month % - Baseline %)

  31. Whole Brain T1 Relaxation Time [ Time Frame: This will be assessed at the baseline visit. ]
    The efficacy of clemastine relative to placebo at increasing T1 relaxation time (measured in seconds) across the whole-brain divided into regions of normal-appearing white matter (NAWM), cortical gray matter, and deep gray matter.

  32. Change from Baseline in Whole Brain T1 Relaxation Time at 3 Months [ Time Frame: This will be assessed at the baseline and 3-month visits. ]
    The efficacy of clemastine relative to placebo at increasing T1 relaxation time (measured in seconds) across the whole-brain divided into regions of normal-appearing white matter (NAWM), cortical gray matter, and deep gray matter. Change = (3-month time - Baseline time)

  33. Change from Baseline in Whole Brain T1 Relaxation Time at 6 Months [ Time Frame: This will be assessed at the baseline and 6-month visits. ]
    The efficacy of clemastine relative to placebo at increasing T1 relaxation time (measured in seconds) across the whole-brain divided into regions of normal-appearing white matter (NAWM), cortical gray matter, and deep gray matter. Change = (6-month time - Baseline time)

  34. Whole Brain UTE Fraction [ Time Frame: This will be assessed at the baseline visit. ]
    The efficacy of clemastine relative to placebo at increasing the UTE fraction (measured in %) across the whole-brain divided into regions of normal-appearing white matter (NAWM), cortical gray matter, and deep gray matter.

  35. Change from Baseline in Whole Brain UTE Values at 3 Months [ Time Frame: This will be assessed at the baseline and 3-month visits. ]
    The efficacy of clemastine relative to placebo at increasing the UTE fraction (measured in %) across the whole-brain divided into regions of normal-appearing white matter (NAWM), cortical gray matter, and deep gray matter. Change = (3-month % - Baseline %)

  36. Change from Baseline in Whole Brain UTE Values at 6 Months [ Time Frame: This will be assessed at the baseline and 6-month visits. ]
    The efficacy of clemastine relative to placebo at increasing the UTE fraction (measured in %) across the whole-brain divided into regions of normal-appearing white matter (NAWM), cortical gray matter, and deep gray matter. Change = (6-month % - Baseline %)

  37. Clemastine Tolerability [ Time Frame: This will be assessed at the baseline visit. ]
    The tolerability of Clemastine in this population. This will include a special focus with regards to fatigue as this is a major symptom for patients suffering from multiple sclerosis.

  38. Change from Baseline in Clemastine Tolerability at 3 Months [ Time Frame: This will be assessed at the baseline and 3-month visits. ]
    The tolerability of Clemastine in this population. This will include a special focus with regards to fatigue as this is a major symptom for patients suffering from multiple sclerosis. Change = (3-month tolerability - Baseline tolerability)

  39. Change from Baseline in Clemastine Tolerability at 6 Months [ Time Frame: This will be assessed at the baseline and 6-month visits. ]
    The tolerability of Clemastine in this population. This will include a special focus with regards to fatigue as this is a major symptom for patients suffering from multiple sclerosis. Change = (6-month tolerability - Baseline tolerability)

  40. Informative Outcomes [ Time Frame: This will be assessed at the baseline visit. ]
    Which secondary or tertiary outcomes are likely to be informative for future remyelinating trials in optic neuritis (and other related indications).

  41. Informative Outcomes at 3 Months [ Time Frame: This will be assessed at the 3-month visit. ]
    Which secondary or tertiary outcomes are likely to be informative for future remyelinating trials in optic neuritis (and other related indications).

  42. Informative Outcomes at 6 Months [ Time Frame: This will be assessed at the 6-month visit. ]
    Which secondary or tertiary outcomes are likely to be informative for future remyelinating trials in optic neuritis (and other related indications).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Written informed consent must be obtained prior to any assessment being performed.
  • Patients diagnosed with relapsing remitting multiple sclerosis and a disease duration of < 15 years
  • Male or female patients aged 18-55 years (inclusive)
  • Use of appropriate contraception during period of trial (women). Before entry women must be:

    • Post-menopausal for at least 1 year OR
    • Surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, male partner vasectomy or otherwise incapable of pregnancy) OR
    • Practicing a highly effective method of birth control if sexually active, including hormonal prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double barrier method (e.g., condoms, diaphragm or cervical cap with spermicidal foam, cream or gel), or male partner sterilization consistent with local regulations regarding use of birth control methods for patients participating in clinical trials, for the duration of their participation in the study OR
    • Not heterosexually active (patients who are not heterosexually active at screening must agree to utilize a highly effective method of birth control if they become heterosexually active during their participation in the study) OR
    • Practicing true abstinence (when this is in line with the preferred and usual lifestyle of the subject) Period abstinence (e.g., calendar, ovulation, symptothermal, post ovulation methods) is not an acceptable method.

Exclusion Criteria:

  • Radiologic identification of marked brain atrophy relative to patients age based on recent MRI and interpretation of expert neuroradiologist or PI
  • New lesion in most recent MRI (within 3 months)
  • Hypersensitivity to clemastine or other arylalkylamine antihistamines, or any of the excipients.
  • Treatment with corticosteroids within 30 days prior to screening.
  • Expanded Disability Status Scale (EDSS) ≥ 4.5
  • History of significant cardiac conduction block.
  • History of cancer.
  • Suicidal ideation or behavior in 6 months prior to baseline.
  • Pregnancy, breastfeeding or planning to become pregnant.
  • Involved with other study protocols simultaneously without prior approval.
  • Concomitant use of any other putative remyelinating therapy as determined by the investigator.
  • Prior treatment with total lymphoid irradiation, T cell or T cell receptor vaccination.
  • Prior treatment with alemtuzumab, mitoxantrone, or cyclophosphamide.
  • Serum creatinine > 1.5 mg/dL; aspartate transaminase (AST), alanine transaminase (ALT), or alkaline phosphatase > 2 times the upper limit of normal. (Reported within 72 hours)
  • History of drug or alcohol abuse within the past year.
  • Untreated B12 deficiency (as determined by B12 serological assessments and metabolites including methylmalonic acid [MMA] and homocysteine) or untreated hypothyroidism.
  • Clinically significant cardiac, metabolic, hematologic, hepatic, immunologic, urologic, endocrinologic, neurologic, pulmonary, psychiatric, dermatologic, allergic, renal, or other major diseases that in the PI's judgment may affect the interpretation of study results or patient safety.
  • History of or presence of clinically significant medical illness or laboratory abnormality that, in the opinion of the investigator would preclude participation in the study
  • Inability to participate in MRI, including extreme claustrophobia.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05359653


Contacts
Layout table for location contacts
Contact: Daniel Casillas, BA 415-745-1304 daniel.casillas@ucsf.edu
Contact: Shivany Y Condor Montes, MPH 415-353-2707 shivany.condormontes@ucsf.edu

Locations
Layout table for location information
United States, California
Sandler Neurosciences Building, Neurological Clinical Research Unit
San Francisco, California, United States, 94107
Contact: Daniel Casillas, BA    415-745-1304    daniel.casillas@ucsf.edu   
Contact: Shivany Y Condor Montes, MPH    415-353-2707    shivany.condormontes@ucsf.edu   
Principal Investigator: Ari J Green, MD         
Sponsors and Collaborators
University of California, San Francisco
United States Department of Defense
Investigators
Layout table for investigator information
Principal Investigator: Ari J Green, MD, MCR University of California, San Francisco
Publications:

Layout table for additonal information
Responsible Party: University of California, San Francisco
ClinicalTrials.gov Identifier: NCT05359653    
Other Study ID Numbers: 22-36052
First Posted: May 4, 2022    Key Record Dates
Last Update Posted: November 2, 2022
Last Verified: October 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by University of California, San Francisco:
multiple sclerosis
mri
brain
spinal cord
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Multiple Sclerosis, Chronic Progressive
Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Clemastine
Antipruritics
Dermatologic Agents
Histamine H1 Antagonists
Histamine Antagonists
Histamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Anti-Allergic Agents